Dimitrios Kouroupis (born 1982 in Athens, Greece), obtained his Biology degree in 2006 (Aristotle University of Thessalonica, Greece), his MSc in Biosciences degree in 2007 (University of Leeds, United Kingdom) and his PhD in Regenerative Medicine in 2012 (University of Leeds, United Kingdom). As an early stage post-doctoral researcher, he contributed to the field of Stem Cell biology of both adult mesenchymal stem cells (MSC) and pluripotent stem cells by investigating their in vitro and in vivo capacity to regenerate soft musculoskeletal tissues (ligaments, tendons and vascular organoids) (2012-2015, University of Ioannina, Biomedical Research Institute-FORTH, Greece). He also worked for a private company on Stem Cell Banking of haematopoietic and mesenchymal stem cells (2016-2017, Omnigen Cell and Tissue Centre, Greece). As a late stage post-doctoral researcher, he investigated MSC musculoskeletal therapies (synovitis and osteoarthritis) with focus on ‘MSC signatures’ which are directly related to specific MSC functions in vivo. On this basis, he was designing innovative methodologies to ex vivo ‘train’ MSC for more robust and effective in vivo personalized therapeutics (2017-2020, University of Miami School of Medicine, Department of Orthopedics, USA). Currently, he is an early stage investigator and junior faculty with a dual appointment at the Department of Orthopedics – UHealth Sports Medicine Institute and the Diabetes Research Institute & Cell Transplant Center, University of Miami, Miller School of Medicine. Throughout his career, he has in depth studied various Cellular Biology and Regenerative Medicine scientific aspects in relationship with cell-based therapeutic approaches for the treatment of musculoskeletal conditions. The development of off-the-shelf novel stem cell therapies to treat musculoskeletal diseases and the generation of innovative stem cell-based therapeutic implants are among his major priorities. Up to date, his research work on Regenerative Medicine and Tissue engineering fields have yielded multiple important publications in high impact factor peer-reviewed journals and podium presentations in international conferences and translated into funding from both EU/UK/USA public and private sources. Furthermore, his research is focused on strengthening our understanding of the intricate underlying biology of Mesenchymal Stem Cell (MSC) in order to support the development of standardized and reproducible pre-clinical protocols, expanding the potential therapeutic application of MSC to various pathological conditions. Consequently, his laboratory contributes with efforts to bring closer basic science and cell-based product manufacturing techniques to potential clinical protocols